Morgan Stanley’s Vyant Bio VYNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-9
Closed -$5 – 7797
2023
Q1
$5 Sell
9
-324
-97% -$258 ﹤0.01% 7685
2022
Q4
$234 Sell
333
-3,677
-92% -$5.98K ﹤0.01% 7629
2022
Q3
$11K Hold
4,010
– – ﹤0.01% 7053
2022
Q2
$18K Sell
4,010
-4
-0.1% -$18 ﹤0.01% 7037
2022
Q1
$29K Sell
4,014
-3,596
-47% -$20.9K ﹤0.01% 6983
2021
Q4
$51K Hold
7,610
– – ﹤0.01% 6803
2021
Q3
$89K Hold
7,610
– – ﹤0.01% 6439
2021
Q2
$142K Buy
7,610
+7,557
+14,258% +$141K ﹤0.01% 6184
2021
Q1
$1K Buy
53
+46
+657% +$1.16K ﹤0.01% 7416
2020
Q4
$0 Hold
7
– – ﹤0.01% 7167
2020
Q3
$0 Buy
+7
New +$132 ﹤0.01% 6881
2020
Q1
– Sell
-3
Closed – – 6785
2019
Q4
$0 Hold
3
– – ﹤0.01% 6834
2019
Q3
$0 Sell
3
-1
-25% -$19 ﹤0.01% 6827
2019
Q2
$0 Sell
4
-80
-95% -$2.5K ﹤0.01% 6811
2019
Q1
$3K Sell
84
-8
-9% -$329 ﹤0.01% 6420
2018
Q4
$3K Sell
92
-32
-26% -$2.7K ﹤0.01% 6388
2018
Q3
$20K Sell
124
-3
-2% -$444 ﹤0.01% 6142
2018
Q2
$17K Buy
127
+19
+18% +$2.87K ﹤0.01% 6188
2018
Q1
$27K Hold
108
– – ﹤0.01% 6067
2017
Q4
$30K Sell
108
-12
-10% -$4.58K ﹤0.01% 5975
2017
Q3
$49K Sell
120
-6
-5% -$3.13K ﹤0.01% 5787
2017
Q2
$74K Sell
126
-7
-5% -$4.09K ﹤0.01% 5744
2017
Q1
$82K Buy
133
+14
+12% +$4.98K ﹤0.01% 5673
2016
Q4
$24K Sell
119
-21
-15% -$4.77K ﹤0.01% 5959
2016
Q3
$37K Buy
140
+3
+2% +$919 ﹤0.01% 5704
2016
Q2
$40K Sell
137
-12
-8% -$4.22K ﹤0.01% 5600
2016
Q1
$63K Buy
149
+13
+10% +$4.86K ﹤0.01% 5516
2015
Q4
$67K Sell
136
-6
-4% -$4.34K ﹤0.01% 5604
2015
Q3
$167K Sell
142
-8
-5% -$12.2K ﹤0.01% 5174
2015
Q2
$266K Buy
150
+111
+285% +$173K ﹤0.01% 5108
2015
Q1
$46K Buy
39
+22
+129% +$26.1K ﹤0.01% 5832
2014
Q4
$17K Sell
17
-23
-58% -$23K ﹤0.01% 6097
2014
Q3
$54K Sell
40
-81
-67% -$116K ﹤0.01% 5714
2014
Q2
$205K Buy
121
+30
+33% +$57.1K ﹤0.01% 5145
2014
Q1
$206K Buy
91
+48
+112% +$123K ﹤0.01% 5106
2013
Q4
$88K Sell
43
-66
-61% -$143K ﹤0.01% 5392
2013
Q3
$333K Buy
+109
New +$187K ﹤0.01% 4599

Other funds holding VYNT

Morgan Stanley's VYNT Position: Q2 2023 in Review

Morgan Stanley sold out of Vyant Bio (VYNT) in Q2 2023, closing a stake of 9 shares — an estimated $5 sold.

Morgan Stanley first reported a position in VYNT in Q3 2013 and held it in 37 quarters. The position peaked at $333K in Q3 2013. 1 fund tracked by Wall St. Rank holds VYNT as of Q2 2023.

  • Morgan Stanley reported no remaining Vyant Bio position as of Q2 2023 after selling out during the quarter.
  • Morgan Stanley sold 9 Vyant Bio shares in Q2 2023, an estimated $5.
  • Morgan Stanley first reported a position in Vyant Bio in Q3 2013 and held it in 37 quarters.
  • Morgan Stanley's Vyant Bio position peaked at $333K in Q3 2013.
  • 1 fund tracked by Wall St. Rank held Vyant Bio as of Q2 2023.

Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.